Literature DB >> 7829984

Evidence for a novel source of relaxin: atrial cardiocytes.

M J Taylor1, C L Clark.   

Abstract

Antibody-directed, complement-induced erythrocyte lysis (reverse hemolytic plaque assay) around atrial cardiocytes was used to determine whether this cell type possesses the capacity to secrete the insulin-like hormone relaxin. After 2h of incubation, 33 +/- 4% (n = 3) of cardiocytes derived from the atria of neonatal rats secreted detectable amounts of immunoreactive relaxin (i.e. formed plaques) when cultured in monolayers. Increased culture time of cardiocytes failed to increase the fraction of cardiocytes that secreted relaxin. The cumulative amount of relaxin secreted after 3h of incubation (plaque area) was 31% greater (P < 0.05) than the amount of hormone present after 1h of incubation, evidence of sustained peptide secretion by cultured cardiocytes. These data suggest that the source of the endogenous ligand for the specific and high-affinity relaxin receptors located in rat atria is the atrial cardiocyte itself. Therefore, relaxin may act via autocrine and/or paracrine routes to regulate cardiovascular structure and/or function.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7829984     DOI: 10.1677/joe.0.143r005

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  11 in total

1.  Protective effect of relaxin in cardiac anaphylaxis: involvement of the nitric oxide pathway.

Authors:  E Masini; G Zagli; J F Ndisang; M Solazzo; P F Mannaioni; D Bani
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

Review 2.  New Insights into biological roles of relaxin and relaxin-related peptides.

Authors:  Jae-Il Park; Chia Lin Chang; Sheau Yu Teddy Hsu
Journal:  Rev Endocr Metab Disord       Date:  2005-12       Impact factor: 6.514

3.  Quantitative autoradiographic studies of relaxin binding in rat atria, uterus and cerebral cortex: characterization and effects of oestrogen treatment.

Authors:  Y Y Tan; J D Wade; G W Tregear; R J Summers
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

4.  Serum relaxin levels as a novel biomarker for detection of acute myocardial infarction.

Authors:  Dongxia Zhang; Yun Wang; Songben Yu; Hua Niu; Xingji Gong; Xia Miao
Journal:  Int J Clin Exp Med       Date:  2015-09-15

5.  N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure.

Authors:  C Fisher; C Berry; L Blue; J J Morton; J McMurray
Journal:  Heart       Date:  2003-08       Impact factor: 5.994

6.  Relaxin promotes growth and maturation of mouse neonatal cardiomyocytes in vitro: clues for cardiac regeneration.

Authors:  Silvia Nistri; Alessandro Pini; Chiara Sassoli; Roberta Squecco; Fabio Francini; Lucia Formigli; Daniele Bani
Journal:  J Cell Mol Med       Date:  2012-03       Impact factor: 5.310

Review 7.  Relaxin as a natural agent for vascular health.

Authors:  Daniele Bani
Journal:  Vasc Health Risk Manag       Date:  2008

8.  Relaxin ameliorates high glucose-induced cardiomyocyte hypertrophy and apoptosis via the Notch1 pathway.

Authors:  Xiao Wei; Yuan Yang; Yin-Jiu Jiang; Jian-Ming Lei; Jing-Wen Guo; Hua Xiao
Journal:  Exp Ther Med       Date:  2017-11-06       Impact factor: 2.447

Review 9.  Relaxin-2 in Cardiometabolic Diseases: Mechanisms of Action and Future Perspectives.

Authors:  Sandra Feijóo-Bandín; Alana Aragón-Herrera; Diego Rodríguez-Penas; Manuel Portolés; Esther Roselló-Lletí; Miguel Rivera; José R González-Juanatey; Francisca Lago
Journal:  Front Physiol       Date:  2017-08-18       Impact factor: 4.566

10.  Male Seminal Relaxin Contributes to Induction of the Post-mating Cytokine Response in the Female Mouse Uterus.

Authors:  Danielle J Glynn; Kee Heng; Darryl L Russell; David J Sharkey; Sarah A Robertson; Ravinder Anand-Ivell; Richard Ivell
Journal:  Front Physiol       Date:  2017-06-19       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.